Just last year, tubastatin A, an HDAC6-selective inhibitor, showed strong anti-ovarian cancer tendencies [150], and the same thailandepsins along with romidepsin showed promising inhibition of ovarian cancer DNA damage response pathways [151]. Here, HDAC6 is linked to ovarian carcinoma.